Agents that directly target immune cells and that are in early stage development (pre-IND through all-comer first-in-human trials) are evaluated in ONCrg’s Emerging Immuno-Oncology report. The field stems from the initial success of the first immune checkpoint inhibitors, ipilimumab, pembrolizumab, and nivolumab in the treatment of cancer. Currently, the development landscape includes a wide range of MOAs and technologies including checkpoint inhibitors, modified cytokines, cell therapies with novel design, oncolytic viruses with auxiliary functions, and bi-specific antibodies with various targets, among others. Combination therapies with IO agents are also explored in this report.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in emerging immuno-oncology to help guide strategic and tactical commercial development decisions for market participants.